Syntara on advancing first-in-class Myelofibrosis therapy with multiple pipeline opportunities
Welcome to the latest HotCopper Capital Compass, where we’ve this week spoken to Syntara Ltd (ASX:SNT) chief Gary Phillips for a high-level overview on the biotech company’s objectives in treating blood cancers and fibrosis, what underpins its value proposition, an...
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| HAO | Ann:Quarterly Report to 31 December 2025 | 30/01/26 | 0 | 115 | |||
|
|||||||
| HAO | Ann:Results of Annual General Meeting | 26/11/25 | 0 | 142 | |||
|
|||||||
| HAO | Ann:Quarterly Update (Price Sensitive) | 30/10/25 | 0 | 210 | |||
|
|||||||
| HAO | Ann:Quarterly Cashflow Report (Price Sensitive) | 30/10/25 | 0 | 220 | |||
|
|||||||
| HAO | Ann:Notice of Annual General Meeting/Proxy Form | 28/10/25 | 0 | 235 | |||
|
|||||||
| HAO | Ann:Annual General Meeting Advanced Notice | 21/10/25 | 0 | 194 | |||
|
|||||||
| HAO | Ann:30 June 2025 (Price Sensitive) | 01/10/25 | 0 | 229 | |||
|
|||||||
| HAO | Ann:Preliminary Final Report 30 June 2025 (Price Sensitive) | 12/09/25 | 0 | 571 | |||
|
|||||||
See All Discussions
Timeline
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
| View More | |||||
NSX News